Sun Pharmaceutical Industries' Q4 FY 2025-26 Quarterly Results

Result Summary

• Sun Pharmaceutical Industries Ltd reported a 6.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.0%.
• Its expenses for the quarter were up by 1.2% QoQ and 15.7% YoY.
• The net profit decreased 19.9% QoQ and increased 25.8% YoY.
• The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 11.3 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharmaceutical Industries Ltd is a prominent player in the pharmaceutical industry, headquartered in India. The company specializes in the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Sun Pharma's product portfolio covers a wide range of therapeutic areas, including cardiology, psychiatry, neurology, gastroenterology, and anti-infectives, making it a key player in both the domestic and international markets. As of the last update, Sun Pharma has been engaged in expanding its global footprint through strategic acquisitions and collaborations, although specific recent developments beyond this are not available.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Sun Pharmaceutical Industries Ltd reported a total income of ₹15,070.29 crores. This represents a decrease of 6.4% compared to the preceding quarter (Q3FY26), where the total income was ₹16,099.38 crores. However, on a year-over-year basis, there was an 11.0% increase from Q4FY25, when the total income was ₹13,571.71 crores. These figures indicate fluctuations in revenue generation over the recent quarters, with an overall positive annual growth rate.

Profitability

For Q4FY26, Sun Pharma achieved a Profit Before Tax (PBT) of ₹3,514.66 crores, which is a 22.7% decline from the previous quarter's PBT of ₹4,548.73 crores. Nevertheless, there was an 8.0% increase in PBT compared to the same quarter of the previous year (Q4FY25) when the PBT stood at ₹3,254.35 crores. The Profit After Tax (PAT) for Q4FY26 was ₹2,709.66 crores, showing a quarter-over-quarter decrease of 19.9% from ₹3,381.17 crores in Q3FY26, but a year-over-year increase of 25.8% from ₹2,153.93 crores in Q4FY25. The tax expense for the quarter was ₹790.94 crores, reflecting a significant reduction from both the previous quarter and the year-ago period.

Operating Metrics

The earnings per share (EPS) for Q4FY26 was ₹11.30, which is a decrease of 19.3% from the previous quarter's EPS of ₹14.00. However, this marks an increase of 25.6% from Q4FY25, when the EPS was ₹9.00. Total expenses for the quarter were ₹11,518.95 crores, reflecting a slight increase of 1.2% from Q3FY26 and a more pronounced increase of 15.7% year-over-year from Q4FY25. These operating metrics suggest variations in cost management and earnings distribution over the recent periods.